Curcumin/Doxorubicin
- Generic Name
- Curcumin/Doxorubicin
IMX-110 in Patients With Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Solid Tumor, AdultAdvanced Solid TumorsBreast CancerOvarian CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Immix Biopharma Australia Pty Ltd
- Target Recruit Count
- 70
- Registration Number
- NCT03382340
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
🇦🇺St George Hospital, Sydney, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath